Portolan Capital Management’s Harvard Bioscience HBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-12,000
| Closed | -$34.2K | – | 140 |
|
|
2024
Q2 | $34.2K | Sell |
12,000
-685,840
| -98% | -$1.95M | ﹤0.01% | 117 |
|
|
2024
Q1 | $2.96M | Buy |
697,840
+25,670
| +4% | +$109K | 0.23% | 103 |
|
|
2023
Q4 | $3.6M | Buy |
672,170
+221,273
| +49% | +$1.18M | 0.31% | 90 |
|
|
2023
Q3 | $1.94M | Sell |
450,897
-332,694
| -42% | -$1.43M | 0.18% | 109 |
|
|
2023
Q2 | $4.3M | Sell |
783,591
-259,955
| -25% | -$1.43M | 0.38% | 76 |
|
|
2023
Q1 | $4.38M | Sell |
1,043,546
-10,754
| -1% | -$45.2K | 0.42% | 78 |
|
|
2022
Q4 | $2.92M | Sell |
1,054,300
-287,791
| -21% | -$797K | 0.29% | 96 |
|
|
2022
Q3 | $3.44M | Sell |
1,342,091
-1,109,770
| -45% | -$2.84M | 0.36% | 95 |
|
|
2022
Q2 | $8.83M | Sell |
2,451,861
-74,928
| -3% | -$270K | 0.89% | 45 |
|
|
2022
Q1 | $15.7M | Sell |
2,526,789
-12,010
| -0.5% | -$74.6K | 1.25% | 22 |
|
|
2021
Q4 | $17.9M | Buy |
2,538,799
+180,789
| +8% | +$1.27M | 1.2% | 30 |
|
|
2021
Q3 | $16.5M | Buy |
2,358,010
+540,133
| +30% | +$3.77M | 1.2% | 34 |
|
|
2021
Q2 | $15.1M | Buy |
1,817,877
+207,064
| +13% | +$1.72M | 1.09% | 36 |
|
|
2021
Q1 | $8.8M | Buy |
1,610,813
+271,631
| +20% | +$1.48M | 0.69% | 60 |
|
|
2020
Q4 | $5.75M | Buy |
1,339,182
+360,115
| +37% | +$1.54M | 0.52% | 73 |
|
|
2020
Q3 | $2.95M | Buy |
979,067
+399,773
| +69% | +$1.2M | 0.33% | 97 |
|
|
2020
Q2 | $1.8M | Buy |
+579,294
| New | +$1.8M | 0.21% | 113 |
|